US: Meeting Held to Discuss Delay of Banning Menthol Cigarettes

Regulations by 2FIRSTS.ai
Dec.21.2023
US: Meeting Held to Discuss Delay of Banning Menthol Cigarettes
US government officials and public health leaders held a meeting to discuss the delayed ban on menthol cigarettes.

According to a report by thehill, there has been a recent meeting between US government officials and public health leaders. This meeting took place following the US government's decision to delay the ban on flavored menthol cigarettes.

 

The meeting, which was not publicly announced, was not officially included in the public agenda. However, government officials had previously held a meeting with tobacco industry lobbyists, including some former senators, last month, in opposition to the proposed ban. Two weeks later, the White House officially announced that the ban would be postponed until at least March.

 

The online conference held this Tuesday, initiated by the "Smoke-Free Youth" campaign, was attended by officials including Robert Califf, the Commissioner of the U.S. Food and Drug Administration (FDA), Xavier Becerra, the Secretary of Health and Human Services (HHS), and Neera Tanden, the White House Domestic Policy Advisor.

 

According to feedback from attendees, the organization of the meeting took place after the announcement of the delay in the ban, during which public health officials questioned industry lobbyists on the reasons behind their ability to meet with senior government officials.

 

In attendance among public health and civil rights leaders were Derrick Johnson, President and CEO of the National Association for the Advancement of Colored People (NAACP); David Satcher, former advocate for disease prevention and the first African American Surgeon General of the United States; Louis Sullivan, former Secretary of the U.S. Department of Health and Human Services (HHS); Yolanda Lawson, Chair of the American Medical Association; as well as board leaders from the American Cancer Society Cancer Action Network, the American Lung Association, and the American Heart Association.

 

The Office of Management and Budget (OMB), which is responsible for regulatory actions, needs to hold meetings with stakeholders interested in the proposed regulations. These meetings are held to gather opinions and are typically not attended by senior officials.

 

Since October, the OMB has held multiple meetings with external organizations regarding policies, including retailers, civil rights groups, and law enforcement officials. According to records, nearly all of the meetings have been with organizations opposed to the ban.

 

The public health organization has been warning that the White House may under pressure decide to indefinitely delay the regulation, especially against the backdrop of Joe Biden's reelection bid as president.

 

According to the initially planned schedule, the new regulations were supposed to be released in August, but were later postponed until the end of the year. As part of its regulatory plan, the White House has now set a new target date for March 2024.

 

The ban on menthol cigarettes has been under consideration for more than a decade and, once implemented, will be one of the most impactful policies since the US FDA began regulating tobacco in 2009. Health officials and tobacco control advocates have stated that this action could potentially save thousands of lives, particularly among African American smokers.

 

According to an FDA report, approximately 85% of African American smokers prefer menthol cigarettes, compared to only 30% among white smokers.

 

However, the proposal of the ban has sparked disagreement among some influential black lawmakers and community members. Critics argue that this foreshadows a longstanding industry practice aimed at targeting black communities and forming alliances with leaders to create chaos.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
Kumulus Vape2026 H1 Revenue Falls 8.3% but Profit Rises 24% as B2B Weakens and Consumer Channels Grow
French vaping company Kumulus Vape reported first-half 2026 revenue of €25.5 million, down 8.3% year over year, as its core B2B distribution business fell 11% to €21.6 million. B2C and store-network revenue rose 5.6% and 17.8%, respectively. Commercial margin increased to 26.3% from 21.7%, while net profit rose 24.1% to €0.8 million. The company attributed the profitability improvement to catalog optimization, logistics restructuring and the ramp-up of Labster, its in-house production unit for proprietary brands.
Market
Sep.17 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italian Financial Police Seize 4.3 Million E-Cigarettes and Smoking Accessories; 28 Reported to Judicial Authorities Across Operations
Italy's Guardia di Finanza announced on October 28 that officers in Latina province had seized approximately 4.3 million e-cigarettes and smoking accessories at an unauthorized warehouse in an operation involving restrictions on the possession and sale of tobacco-related products. Another 300,000 suspected counterfeit or unsafe items were confiscated during separate inspections, bringing total seizures across the operations to more than 4.6 million products. Twenty-eight people were reported to judicial authorities over suspected smuggling and counterfeiting offenses. Officials did not disclose separate vape quantities, the value of the merchandise or alleged violations associated with individual brands.
Enforcement
Oct.29
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27